Who makes enoblituzumab plus ipilimumab?

enoblituzumab plus ipilimumab is developed by MacroGenics.

What development phase is enoblituzumab plus ipilimumab in?

enoblituzumab plus ipilimumab is in Phase 1.

Last reviewed 2026-04-20 · How we verify

enoblituzumab plus ipilimumab

MacroGenics · Phase 1 active Biologic Quality 0/100

At a glance

Generic name	enoblituzumab plus ipilimumab
Also known as	enoblituzumab (MGA271); ipilimumab (Yervoy)
Sponsor	MacroGenics
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

enoblituzumab plus ipilimumab CI brief — competitive landscape report
enoblituzumab plus ipilimumab updates RSS · CI watch RSS
MacroGenics portfolio CI